ivabradine hydrochloride - Profile

What are the generic sources for ivabradine hydrochloride and what is the scope of patent protection?

Ivabradine hydrochloride is the generic ingredient in two branded drugs marketed by Amgen Inc, Alembic, Annora Pharma, Bionpharma, Ingenus Pharms Llc, MSN, and Zydus Pharms, and is included in seven NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ivabradine hydrochloride has ninety-seven patent family members in forty-two countries.

Summary for ivabradine hydrochloride

International Patents:	97
US Patents:	4
Tradenames:	2
Applicants:	7
NDAs:	7
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ivabradine hydrochloride

Paragraph IV (Patent) Challenges for IVABRADINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CORLANOR	Tablets	ivabradine hydrochloride	5 mg and 7.5 mg	206143	6	2019-10-15

US Patents and Regulatory Information for ivabradine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amgen Inc	CORLANOR	ivabradine hydrochloride	TABLET;ORAL	206143-001	Apr 15, 2015		DISCN	Yes	No	7,879,842*PED				Y
Amgen Inc	CORLANOR	ivabradine hydrochloride	TABLET;ORAL	206143-001	Apr 15, 2015		DISCN	Yes	No	7,361,649*PED				Y
Amgen Inc	CORLANOR	ivabradine hydrochloride	TABLET;ORAL	206143-001	Apr 15, 2015		DISCN	Yes	No	7,361,650*PED				Y
Amgen Inc	CORLANOR	ivabradine hydrochloride	TABLET;ORAL	206143-001	Apr 15, 2015		DISCN	Yes	No	7,867,996*PED				Y
Amgen Inc	CORLANOR	ivabradine hydrochloride	TABLET;ORAL	206143-002	Apr 15, 2015		DISCN	Yes	No	7,879,842*PED				Y

International Patents for ivabradine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Argentina	052926	FORMA CRISTALINA GAMA DEL CLORHIDRATO DE IVABRADINA, UN PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICIONES QUE LA CONTIENEN
Eurasian Patent Organization	008464	β-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ (BETA-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT)
World Intellectual Property Organization (WIPO)	2006092492
South Africa	200601762	ß-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Costa Rica	8248	FORMA CRISTALINA BETA DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN

Investment Scenario and Fundamentals Analysis of Ivabradine Hydrochloride

Last updated: February 19, 2026

What is Ivabradine Hydrochloride?

Ivabradine hydrochloride is a selective sinus node inhibitor approved primarily for chronic heart failure and angina pectoris. It reduces heart rate by inhibiting the funny current (If) in sinoatrial node cells. Marketed under brand names such as Corlanor (by Novartis), ivabradine has gained regulatory approval in multiple jurisdictions, including the US, EU, and Japan.

Market Overview and Key Drivers

Market Size and Growth

• Global Heart Failure Market (2022): Valued at approximately $15.2 billion, expected to grow at a CAGR of 8.4% through 2030 (Grand View Research).
• Heart Rate Management Segment: Ivabradine is a notable component, with estimated sales of $1.2 billion in 2022.
• Geographical Penetration: US accounts for roughly 40% of sales, with Europe at 35% and Asia-Pacific emerging as a growth region.

Leading Players and Competitive Landscape

Company	Product	Estimated 2022 Sales	Market Share	Patent Status
Novartis	Corlanor (ivabradine)	$1.2B	65%	Patent expiry in 2030 (assumed)
Servier	Procoralan	Regional	N/A	Patent status varies by country
Others	Generic formulations	N/A	35%	Slightly delayed patent expiration

Unaffiliated Market Factors

• Regulatory pathways for generic ivabradine are established, with patent cliffs anticipated around 2030.
• Pricing dynamics depend on regional healthcare policies, especially in trial markets like the US and EU.

Clinical and Regulatory Fundamentals

Efficacy and Indications

• Clinical trials demonstrate significant heart rate reduction (~15 bpm) with improved outcomes in heart failure patients (CIBIS-II, SHIFT studies).
• Approved indications include chronic stable angina and heart failure with reduced ejection fraction (HFrEF).

Safety Profile

• Common side effects: luminous phenomena, bradycardia, hypertension.
• Contraindications: sinoatrial block, severe hypotension.

Regulatory Status

• US: Approved since 2015 under FDA.
• EU: Approved since 2010.
• Japan: Approved for heart failure and angina.

Investment Fundamentals

Patent and Exclusivity Considerations

• Patent expiry estimated around 2030, with potential for extensions based on formulation patents.
• Patent cliffs for branded formulations will open opportunities for generics, decreasing prices and affecting margins.

R&D Pipeline and Pipeline Drugs

• No ongoing Phase III programs seeking to expand indications.
• Novel formulations or delivery mechanisms under preclinical evaluation may influence future exclusivities.

Commercial Risks and Opportunities

• Market Risks: Entry of generics post-2029-2030 could reduce revenues significantly.
• Regulatory Risks: Changes in approval standards or reimbursement policies could limit sales.
• Strategic Opportunities: Expansion into new indications (e.g., atrial fibrillation management) or combination therapies.

Financial Metrics

Metric	Description	Benchmark
Market Penetration	Degree of market share in target indications	65% for Corlanor in heart failure
Price Premium	Difference from generics	10-20% for branded ivabradine in premium markets
R&D Investment	Estimated $100 million annually	Industry average for small-molecule drugs

Competitive Position and Investment Outlook

• Ivabradine's niche position in heart failure and angina offers stability.
• The patent expiration in 2030 introduces regulatory and market risks.
• Future value depends on successfully capturing additional indications or lifecycle extensions.

Key Considerations for Investors

• Patent expiry: 2030 marks a significant pivot point; preparations for generic competition should be factored into valuation.
• Pipeline viability: Current pipeline does not promise immediate future growth.
• Market penetration: Growth in emerging markets could offset some revenue decline in mature markets.
• Regulatory risk: Changes may influence reimbursement or approval in key markets.

Key Takeaways

Ivabradine hydrochloride remains a relevant drug within the cardiovascular segment, with a stable market presence driven by its efficacy in heart failure and angina. Patent expiration in approximately eight years will likely precipitate increased generic competition, pressuring margins. The company's ability to innovate or expand indications may influence valuation post-patent expiry. Investors should focus on regulatory developments, patent extensions, and geographic expansion to assess long-term potential.

FAQs

1. When is patent expiration for ivabradine hydrochloride anticipated?
Patent expiration is projected around 2030, considering current patent protections and jurisdictions.

2. What are the major risks associated with investing in ivabradine?
Patent cliff effects, generic entry, regulatory changes, and limited pipelines pose primary risks.

3. Are there existing regulatory hurdles for generic versions?
Regulatory pathways are well-established, but patent litigation may delay market entry.

4. What potential indications could expand ivabradine’s market?
Atrial fibrillation and other rhythm disorders are under investigation but not currently approved.

5. How does pricing differ between branded and generic ivabradine?
Branded formulations typically command a 10-20% premium, with significant discounts possible for generics.

---

References

[1] Grand View Research. (2022). Heart failure drugs market size, share & trends analysis report.
[2] U.S. Food and Drug Administration. (2015). FDA approval letter for Corlanor.
[3] European Medicines Agency. (2010). Summary of product characteristics for Procoralan.
[4] ClinicalTrials.gov. (n.d.). Ivabradine clinical trials for additional indications.